• Earlier this month, Vaxcyte announced that it has dosed the first participant in its Phase 1, first-in-human trial of VAX-A1, an investigational vaccine targeting Group A Streptococcus, with topline safety and tolerability data expected in the second half of 2027.
• This milestone advances Vaxcyte’s pipeline into human testing for a pathogen that currently has no approved vaccine, highlighting the company’s effort to address a significant infectious disease burden.
• We’ll now examine how initiating first-in-human testing for VAX-A1 could reshape Vaxcyte’s investment narrative and pipeline diversification story.

Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Vaxcyte Investment Narrative Recap

To own Vaxcyte, you need to believe its pneumococcal franchise, led by VAX-31, can eventually transition the company from zero revenue to a sustainable vaccine business. The key near term catalyst remains the OPUS-1 Phase 3 readout for adult VAX-31 in Q4 2026, while the biggest risk is continued high cash burn if late stage data or timelines disappoint. The new VAX-A1 first in human milestone is encouraging for diversification, but does not materially change that near term focus.

The VAX-A1 Phase 1 start fits alongside a busy clinical calendar anchored by VAX-31. In February 2026, Vaxcyte reiterated that OPUS-1 adult data are expected in Q4 2026, with OPUS-2 and OPUS-3 following in the first half of 2027, and infant VAX-31 Phase 2 topline mid 2026. Against this backdrop, VAX-A1’s progress adds a second potential franchise, but the timing and importance of those late stage VAX-31 readouts still dominate the upcoming catalyst stack.

Yet beneath these pipeline milestones, investors should also be aware of the risk that rising R&D and manufacturing costs could outpace the current cash runway guidance and ...

Vaxcyte’s narrative projects $224.6 million revenue and $28.1 million earnings by 2029. This implies an earnings increase of about $794.7 million from -$766.6 million today.

Uncover how Vaxcyte's forecasts yield a $109.00 fair value, a 112% upside to its current price.

Exploring Other Perspectives

By contrast, the most pessimistic analysts saw only about US$15.3 million of revenue and US$1.7 million of earnings by 2029, reminding you that even with VAX A1’s first dosing, opinions on whether early stage uncertainty and extra proof of concept work will pay off can differ widely and may evolve as this new data arrives.

Explore 3 other fair value estimates on Vaxcyte - why the stock might be worth over 3x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Vaxcyte research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Vaxcyte research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Vaxcyte's overall financial health at a glance.

Seeking Other Investments?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 45 companies with promising cash flow potential yet trading below their fair value.
• Explore 31 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.